Global leaders in life sciences and nonclinical drug development, Envigo (Huntingdon, UK) and LabCorp (NC, USA), have signed an innovative agreement in a bid to expand nonclinical drug development capabilities and create an independent research models provider.
With the reality of Brexit already impacting the UK’s clinical trials environment, Zamas Lam (QPS; DE, USA) discusses the effect this will have on bioanalytical research, and suggests 10 questions to ask when relocating UK-based preclinical and bioanalysis research projects.
Charles River Laboratories have signed an agreement to acquire Citoxlab for $510 million in a deal that aims to expand their global scale and scientific service portfolio.
In this Bioanalysis Zone interview, Pegah Jalili (MilliporeSigma) discusses her current work in analytical R&D of biotherapeutic characterization and quantification, and what she thinks the future looks like for this field of bioanalysis.
We celebrate Chinese New Year by interviewing Fan Jin (Covance; NJ, USA), who discusses the history, background and aims behind the China Bioanalytical Forum.
Bristol-Myers Squibb (NY, USA) have announced that they will be acquiring Celgene (NJ, USA) this year for a cost of $74 billion.
Richard Hucker (A4P Codescribes key trends, challenges and what the future may hold for bioanalytical outsourcing.
Find out what Marco Michi (Aptuit) has to say about the future of bioanalytical outsourcing, in this expert interview.
Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum
In this manuscript, the European Bioanalysis Forum presents additional practice guidance on the use of flow cytometry in the support of drug development programs and addresses areas that are not covered in the previous publications.
Find out what Kevin Vernarec (QPS) thinks about how outsourcing might change in the future in this expert interview.